Orion Oyj

ORNAV

Equity

ISIN FI0009014369 / Valor 2553360

NASDAQ Helsinki Ltd, Equities (2025-11-21)

EUR 59.90+0.17%

Orion Oyj
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Orion Oyj is a Finnish pharmaceutical company that focuses on the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. The company operates globally, leveraging partnerships and collaborations to enhance its capabilities across the entire value chain. Orion's product portfolio includes a range of prescription medicines, self-care products, and veterinary medicines, with a strong emphasis on central nervous system disorders, oncology, and respiratory diseases. The company is also involved in the development of diagnostic tests and provides contract manufacturing services. Through strategic alliances and a commitment to innovation, Orion aims to address unmet medical needs and improve patient outcomes worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Earnings Beat Expectations

In Q3 2023, Orion Oyj achieved revenues of €417 million, exceeding analyst predictions by 10%. The statutory earnings per share reached €0.59, which was 14% above the forecasted models, demonstrating robust financial performance.

Revised Forecasts for 2025

Following the latest results, the consensus forecast for 2025 projects Orion Oyj's revenues to grow to €1.77 billion, reflecting a 5.3% increase compared to the past 12 months. Additionally, statutory EPS is expected to rise by 12% to €3.02, up from earlier estimates of €2.64.

Price Target Increased

Analysts have responded to the strong quarterly performance by raising Orion Oyj's price target by 6.4% to €66.75 per share. The range of analyst estimates now spans from €46.00 to €77.00, indicating a moderate consensus on the stock’s potential growth.

Growth Outpacing Industry

Orion Oyj is projected to achieve an annualized revenue growth of 11% by the end of 2025, significantly outperforming the industry average of 5.7%. This accelerated growth rate highlights Orion's strong market position and effective business strategies.

Bottom Line

The consensus upgrade in earnings per share and revenue forecasts reflects increased optimism about Orion Oyj's future performance. With expectations of faster growth than the industry and an elevated price target, the company's outlook remains positive for investors.

Summarized from source with an LLMView Source

Key figures

35.8%1Y

23.4%3Y

50.3%5Y

Performance

30.0%1Y

27.1%3Y

28.0%5Y

Volatility